- Home
- NVCT
NVCT
Nuvectis Pharma Inc.
as 10-22-2024 4:00pm EST
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
| Founded: | 2020 | Country: | United States |
| Employees: | N/A | City: | FORT LEE |
| Market Cap: | 119.4M | IPO Year: | 2022 |
| Target Price: | $21.00 | AVG Volume (30 days): | 104.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.28 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.85 - $12.10 | Next Earning Date: | 11-06-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Nuvectis Pharma Inc. News
NVCT Breaking Stock News: Dive into NVCT Ticker-Specific Updates for Smart Investing
GlobeNewswire
16 days ago
Nuvectis Pharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
Simply Wall St.
a month ago
Here's Why We're Watching Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Situation
Business Wire
a month ago
PESG Releases Report on Nuvectis Pharma: With Summit Therapeutics Threatening to Dethrone Merck's Keytruda, Nuvectis' NXP900 is One to Watch
GlobeNewswire
2 months ago
Nuvectis Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Pharmaceutical Technology
2 months ago
Nuvectis’ NXP800 gains FDA ODD for cancer treatment
GlobeNewswire
2 months ago
Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal Cancers
Simply Wall St.
2 months ago
Positive Signs As Multiple Insiders Buy Nuvectis Pharma Stock
MT Newswires
2 months ago
Nuvectis Pharma's NXP800 Gets US FDA Orphan Drug Designation
Compare NVCT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NVCT Nuvectis Pharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.